Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.60 |
| ▸ | PLK1 | P53350 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.51 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.51 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13246837 | 0.95 | L3MBTL1 (0.55) | L3MBTL1PLK1MAPTGAAALDH1A1 | |
| SCHEMBL13246828 | 0.88 | RARB (0.63) | L3MBTL1ALDH1A1TP53TSHRPLA2G4B | |
| SCHEMBL15503238 | 0.88 | TP53 (0.69) | GAATP53TSHRPLA2G4B | |
| SCHEMBL13246798 | 0.88 | TP53 (0.69) | GAATP53TSHRPLA2G4B | |
| SCHEMBL13246800 | 0.88 | TP53 (0.69) | GAATP53TSHRPLA2G4B | |
| SCHEMBL13246799 | 0.88 | TP53 (0.69) | GAATP53TSHRPLA2G4B | |
| SCHEMBL13246801 | 0.88 | TP53 (0.69) | GAATP53TSHRPLA2G4B | |
| SCHEMBL13246802 | 0.88 | TP53 (0.69) | GAATP53TSHRPLA2G4B | |
| SCHEMBL402554 | 0.88 | L3MBTL1 (0.58) | L3MBTL1PLK1MAPTGAAALDH1A1 | |
| SCHEMBL14750868 | 0.88 | L3MBTL1 (0.58) | L3MBTL1PLK1MAPTGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731967-B2 | Inhibitors of TRIM33 and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230139366-A1 | BRARTEMICIN ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2023-05-04 | — | — | US | disclosed |
| US-8877954-B2 | Functionalized nanoparticles | BASF SE (DE) | 2014-11-04 | — | — | US | disclosed |
| US-8449095-B2 | Radiation curable solid ink compositions suitable for transfuse printing applications | XEROX CORPORATION (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120013690-A1 | RADIATION CURABLE SOLID INK COMPOSITIONS SUITABLE FOR TRANSFUSE PRINTING APPLICATIONS | XEROX CORPORATION (US) | 2012-01-19 | — | — | US | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139366-A1 | BRARTEMICIN ANALOGUES | RXFP1, RXFP2, RXFP4 | L3MBTL1 4715/4885PLK1 2851/4885MAPT 4232/4885 |
| US-11731967-B2 | Inhibitors of TRIM33 and methods of use | TRIM33, TRIM28, TRIM4 | L3MBTL1 487/4885PLK1 1011/4885MAPT 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.